Picture of NPT Co logo

311A NPT Co Share Price

0.000.00%
jp flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-3.43%
3m-11.97%
6m-10.31%
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-75.99%
Return on Equity-329.71%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Oct 202531st Oct 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of NPT Co EPS forecast chart

Profile Summary

NPT Co Ltd is a Japan-based company engaged in the clinical development of novel drugs and therapies for personalized medicine. The Company operates through the Pharmaceutical Development segment. The Company specializes in oncology, develops modalities using regenerative medicine technology for cancer, conducts clinical trials under the approval of the Pharmaceuticals and Medical Devices Agency, obtains approval to manufacture and market regenerative medicine products, and then works to sell them in the market. The modality to be developed is the Personalized Antigen Presenting Cell Vaccine (PAPC vaccine). The PAPC vaccine is a cancer immuno-cell therapy in which mutant peptides derived from a genetic mutation called neo-antigen peptide expressed in the patient's cancer cells are loaded onto antigen-presenting cells obtained from the same patient, which are then returned to the patient's body. The Company is developing a PAPC vaccine as a modality for patients with esophageal cancer.

Directors

    Last Annual
    October 31st, 2024
    Last Interim
    April 30th, 2025
    Incorporated
    November 1st, 2018
    Public Since
    January 30th, 2025
    No. of Employees
    7
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    jp flag iconTokyo Stock Exchange
    Shares in Issue
    4,870,700
    Blurred out image of a map
    Address
    KOTO-KU, 135-0063
    Web
    https://neopt.jp/
    Phone
    +81 364557150
    Auditors
    Shisai Audit

    311A Share Price Performance

    Similar to 311A

    Picture of 3-D Matrix logo

    3-D Matrix

    jp flag iconTokyo Stock Exchange

    Picture of AnGes logo

    AnGes

    jp flag iconTokyo Stock Exchange

    Picture of BrightPath Biotherapeutics Co logo

    BrightPath Biotherapeutics Co

    jp flag iconTokyo Stock Exchange

    Picture of Carna Biosciences logo

    Carna Biosciences

    jp flag iconTokyo Stock Exchange

    Picture of Chiome Bioscience logo

    Chiome Bioscience

    jp flag iconTokyo Stock Exchange

    FAQ